These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 27702846)
1. Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Flevari P; Leftheriotis D; Repasos E; Katsaras D; Katsimardos A; Lekakis J Europace; 2017 Jan; 19(1):127-131. PubMed ID: 27702846 [TBL] [Abstract][Full Text] [Related]
2. Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Theodorakis GN; Leftheriotis D; Livanis EG; Flevari P; Karabela G; Aggelopoulou N; Kremastinos DT Europace; 2006 Mar; 8(3):193-8. PubMed ID: 16627439 [TBL] [Abstract][Full Text] [Related]
3. Minor psychiatric disorders and syncope: the role of psychopathology in the expression of vasovagal reflex. Leftheriotis D; Michopoulos I; Flevari P; Douzenis A; Koborozos C; Kostopoulou A; Theodorakis GN; Lykouras L; Kremastinos DT Psychother Psychosom; 2008; 77(6):372-6. PubMed ID: 18716422 [TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of psychological distress and psychiatric morbidity in recurrent vasovagal and unexplained syncope. D'Antono B; Dupuis G; St-Jean K; Lévesque K; Nadeau R; Guerra P; Thibault B; Kus T J Psychosom Res; 2009 Sep; 67(3):213-22. PubMed ID: 19686877 [TBL] [Abstract][Full Text] [Related]
5. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. Flevari P; Livanis EG; Theodorakis GN; Zarvalis E; Mesiskli T; Kremastinos DT J Am Coll Cardiol; 2002 Aug; 40(3):499-504. PubMed ID: 12142117 [TBL] [Abstract][Full Text] [Related]
6. The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope. Gracie J; Newton JL; Norton M; Baker C; Freeston M Europace; 2006 Aug; 8(8):636-43. PubMed ID: 16864617 [TBL] [Abstract][Full Text] [Related]
11. Reflex syncope, anxiety level, and family history of cardiovascular disease in young women: case-control study. Zyśko D; Szewczuk-Bogusławska M; Kaczmarek M; Agrawal AK; Rudnicki J; Gajek J; Melander O; Sutton R; Fedorowski A Europace; 2015 Feb; 17(2):309-13. PubMed ID: 25179650 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials. Behnoush AH; Yazdani K; Khalaji A; Tavolinejad H; Aminorroaya A; Jalali A; Tajdini M Heart Rhythm; 2023 Mar; 20(3):448-460. PubMed ID: 36509319 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological norepinephrine transporter inhibition for the prevention of vasovagal syncope in young and adult subjects: A systematic review and meta-analysis. Lei LY; Raj SR; Sheldon RS Heart Rhythm; 2020 Jul; 17(7):1151-1158. PubMed ID: 32151742 [TBL] [Abstract][Full Text] [Related]
14. Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). Raj SR; Faris PD; Semeniuk L; Manns B; Krahn AD; Morillo CA; Benditt DG; Sheldon RS; Am Heart J; 2016 Apr; 174():89-94. PubMed ID: 26995374 [TBL] [Abstract][Full Text] [Related]
15. Reduced quality of life and greater psychological distress in vasovagal syncope patients compared to healthy individuals. Ng J; Sheldon RS; Ritchie D; Raj V; Raj SR Pacing Clin Electrophysiol; 2019 Feb; 42(2):180-188. PubMed ID: 30488466 [TBL] [Abstract][Full Text] [Related]
16. Can prodromal symptoms predict recurrence of vasovagal syncope? Fazelifar AF; Basiri HA; Tolooie A; Haghjoo M; Barakpour H; Emkanjoo Z; Abkenar HB; Zeighami M; Asgari F; Sadr-Ameli MA Cardiol J; 2008; 15(5):446-50. PubMed ID: 18810720 [TBL] [Abstract][Full Text] [Related]
17. Heart rate recovery and diastolic blood pressure ratio on the treadmill test predict an induction and recurrence of vasovagal syncope. Choi YJ; Kang KW; Jang SH; Kim JG; Lee SJ; Jung KT Korean J Intern Med; 2019 Mar; 34(2):315-323. PubMed ID: 29240992 [TBL] [Abstract][Full Text] [Related]
18. Influence of the recurrent syncope episodes on neurocognitive functions in patients with vasovagal syncope. Jędrzejczyk-Spaho J; Pietrucha AZ; Borowiec A; Bzukała I; Wnuk M; Konduracka E; Nessler J Pol Merkur Lekarski; 2017 Mar; 42(249):106-109. PubMed ID: 28333901 [TBL] [Abstract][Full Text] [Related]
19. Strategy for the management of vasovagal syncope. Bloomfield DM Drugs Aging; 2002; 19(3):179-202. PubMed ID: 12027777 [TBL] [Abstract][Full Text] [Related]
20. A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the Prevention of Syncope Trial VI. Sheldon RS; Lei L; Guzman JC; Kus T; Ayala-Paredes FA; Angihan J; Safdar S; Maxey C; Bennett G; Raj SR Europace; 2019 Nov; 21(11):1733-1741. PubMed ID: 31538180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]